179 related articles for article (PubMed ID: 29166798)
1. GRK2 as a therapeutic target for heart failure.
Cannavo A; Komici K; Bencivenga L; D'amico ML; Gambino G; Liccardo D; Ferrara N; Rengo G
Expert Opin Ther Targets; 2018 Jan; 22(1):75-83. PubMed ID: 29166798
[TBL] [Abstract][Full Text] [Related]
2. GRK2 inhibition in heart failure: something old, something new.
Lymperopoulos A; Rengo G; Koch WJ
Curr Pharm Des; 2012; 18(2):186-91. PubMed ID: 22229578
[TBL] [Abstract][Full Text] [Related]
3. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction.
Lymperopoulos A; Rengo G; Gao E; Ebert SN; Dorn GW; Koch WJ
J Biol Chem; 2010 May; 285(21):16378-86. PubMed ID: 20351116
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression.
Travers JG; Kamal FA; Valiente-Alandi I; Nieman ML; Sargent MA; Lorenz JN; Molkentin JD; Blaxall BC
J Am Coll Cardiol; 2017 Aug; 70(8):958-971. PubMed ID: 28818206
[TBL] [Abstract][Full Text] [Related]
5. GRK2 in the heart: a GPCR kinase and beyond.
Huang ZM; Gao E; Chuprun JK; Koch WJ
Antioxid Redox Signal; 2014 Nov; 21(14):2032-43. PubMed ID: 24702056
[TBL] [Abstract][Full Text] [Related]
6. [The Role of GRK2 and Its Potential as a New Therapeutic Target in Diabetic Vascular Complications].
Taguchi K
Yakugaku Zasshi; 2015; 135(8):961-7. PubMed ID: 26234354
[TBL] [Abstract][Full Text] [Related]
7. GRK2 as a novel gene therapy target in heart failure.
Rengo G; Lymperopoulos A; Leosco D; Koch WJ
J Mol Cell Cardiol; 2011 May; 50(5):785-92. PubMed ID: 20800067
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction.
Schumacher SM; Gao E; Zhu W; Chen X; Chuprun JK; Feldman AM; Tesmer JJ; Koch WJ
Sci Transl Med; 2015 Mar; 7(277):277ra31. PubMed ID: 25739765
[TBL] [Abstract][Full Text] [Related]
9. GRK2 in cardiovascular disease and its potential as a therapeutic target.
Ferrero KM; Koch WJ
J Mol Cell Cardiol; 2022 Nov; 172():14-23. PubMed ID: 35878706
[TBL] [Abstract][Full Text] [Related]
10. GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy.
Lieu M; Koch WJ
Expert Opin Ther Targets; 2019 Mar; 23(3):201-214. PubMed ID: 30701991
[TBL] [Abstract][Full Text] [Related]
11. Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy.
Cannavo A; Liccardo D; Koch WJ
Front Physiol; 2013 Sep; 4():264. PubMed ID: 24133451
[TBL] [Abstract][Full Text] [Related]
12. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure.
Rengo G; Leosco D; Zincarelli C; Marchese M; Corbi G; Liccardo D; Filippelli A; Ferrara N; Lisanti MP; Koch WJ; Lymperopoulos A
Am J Physiol Heart Circ Physiol; 2010 Jun; 298(6):H2032-8. PubMed ID: 20304818
[TBL] [Abstract][Full Text] [Related]
13. The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development.
Hullmann J; Traynham CJ; Coleman RC; Koch WJ
Pharmacol Res; 2016 Aug; 110():52-64. PubMed ID: 27180008
[TBL] [Abstract][Full Text] [Related]
14. GRK2 at the control shaft of cellular metabolism.
Ciccarelli M; Cipolletta E; Iaccarino G
Curr Pharm Des; 2012; 18(2):121-7. PubMed ID: 22229580
[TBL] [Abstract][Full Text] [Related]
15. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia.
Ciccarelli M; Chuprun JK; Rengo G; Gao E; Wei Z; Peroutka RJ; Gold JI; Gumpert A; Chen M; Otis NJ; Dorn GW; Trimarco B; Iaccarino G; Koch WJ
Circulation; 2011 May; 123(18):1953-62. PubMed ID: 21518983
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
Zhang Q; Hu L; Chen L; Li H; Wu J; Liu W; Zhang M; Yan G
Inflammopharmacology; 2018 Aug; 26(4):1081-1091. PubMed ID: 29247373
[TBL] [Abstract][Full Text] [Related]
17. Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure.
Rengo G; Galasso G; Femminella GD; Parisi V; Zincarelli C; Pagano G; De Lucia C; Cannavo A; Liccardo D; Marciano C; Vigorito C; Giallauria F; Ferrara N; Furgi G; Filardi PP; Koch WJ; Leosco D
Eur J Prev Cardiol; 2014 Jan; 21(1):4-11. PubMed ID: 23689525
[TBL] [Abstract][Full Text] [Related]
18. G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart.
Pfleger J; Gross P; Johnson J; Carter RL; Gao E; Tilley DG; Houser SR; Koch WJ
J Mol Cell Cardiol; 2018 Oct; 123():108-117. PubMed ID: 30171848
[TBL] [Abstract][Full Text] [Related]
19. Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.
Reinkober J; Tscheschner H; Pleger ST; Most P; Katus HA; Koch WJ; Raake PW
Gene Ther; 2012 Jun; 19(6):686-93. PubMed ID: 22336718
[TBL] [Abstract][Full Text] [Related]
20. G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism.
Woodall MC; Ciccarelli M; Woodall BP; Koch WJ
Circ Res; 2014 May; 114(10):1661-70. PubMed ID: 24812353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
